MedTrace Logo

Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)

NCT06229041 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 472

Last updated 2024-01-29

No results posted yet for this study

Summary

The goal of this clinical trial is to compare the PCR rate between Total Neoadjuvant Treatment ±Immunotherapy in high risk locally advanced rectal cancer. The main questions it aims to answer are:

* The PCR rate between the two groups
* The 3years DFS between the two groups
* Chemoradiotherapy and immunotherapy toxicity
* Postoperative complications Participants will receive total neoadjuvant treatment ±immunotherapy followed by surgery.

Researchers will compare neoadjuvant treatment ±immunotherapy to see the PCR rate.

Conditions

Interventions

DRUG

Camrelizumab ＋Immunotherapy

Camrelizumab was used in preoperative treatment.

Sponsors & Collaborators

  • Beijing Nanjiao Cancer Hospital

    collaborator UNKNOWN

  • Peking University Cancer Hospital & Institute

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-29
Primary Completion
2027-10-01
Completion
2029-10-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06229041 on ClinicalTrials.gov